Homepage > Company > Media > Pharma News > 2017 > PharmaJet, Invectys enter Phase 2 cancer vaccine trial

PharmaJet, Invectys enter Phase 2 cancer vaccine trial

Needle-free injection technology company PharmaJet, based in Golden, Colo., will be working with French biopharma company Invectys to test Invectys' therapeutic cancer vaccine. The Phase 2 trial is for INVAC-1, which uses PharmaJet’s needle-free injection system and is an immunotherapeutic DNA vaccine meant to treat cancer, the companies said

“We believe the PharmaJet Needle-free device offers many advantages to patients and providers including less pain and stress, elimination of needles and provides a more precise and consistent method for vaccine delivery,” Invectys CEO Pierre Langlade Demoyen said.

PharmaJet said that it has previously tested its Tropis needle-free injection system in huyman and animal clinical trials without evidence of safety concerns.

“We are pleased that the PharmaJet Tropis Intradermal device has been chosen as the method of administration for this important cancer immunotherapy vaccine development.” PharmaJet CEO and chairman Ron Lowy said. “The Needle-free device is safe, fast and easy to administer, and has already been used successfully in numerous clinical studies for nucleic acid (DNA or RNA) vaccine delivery.”

December 20, 2017

http://www.drugstorenews.com/

Read also

Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for the Treatment of Non-Alcoholic Steatohepatitis (NASH)

Pfizer Inc. (NYSE: PFE) announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Pfizer’s investigational combination therapy for the treatment of non-alcoholi...

NICE Recommends Sanofi and Regeneron’s Libtayo for CSCC

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Sanofi and Regeneron’s Libtayo (cemiplimab) for National Health Service (NHS) use in the treatment of patients ...

United Therapeutics’ Tyvaso DPI Approved for Rare High Blood Pressure Disease

The FDA has approved United Therapeutics’ Tyvaso DPI (trepostinil) in an inhaled powder formulation for patients with pulmonary arterial hypertension, a rare type of high blood pressure dis...

UCLA Researchers Identify HIV Drug That Could Combat Memory Loss

Researchers at the University of California, Los Angeles have identified a neurological mechanism behind memory linking.